TP53 and sarcoma: Van Boxtel et al. [18] used N-ethyl-N-nitrosourea-driven target-selected mutagenesis to obtain Tp53 knockout rats and reported that both null Tp53 homozygotes and Tp53 heterozygotes start to develop lethal tumors, mainly sarcomas, at 4 and 8 months of age, respectively.